A retrospective study of efficacy and safety of toripalimab combined with chemoradiotherapy in recurrent or advanced cervical cancer patients
Latest Information Update: 16 Nov 2021
Price :
$35 *
At a glance
- Drugs Toripalimab (Primary) ; Antineoplastics
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2021 New trial record
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress